Navigation Links
Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results
Date:3/7/2012

SAN DIEGO, March 7, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today financial results for the fourth quarter and fiscal year ended December 31, 2011, and provided an update on the DIFICID® (fidaxomicin) launch for the first two months of 2012.

2011 Financial Highlights

  • Total revenues in 2011 were $145 million, compared to $1.5 million in 2010
  • DIFICID net sales in 2011 were $21.5 million, compared to no DIFICID sales in 2010
  • DIFICID net sales in the fourth quarter were $11.0 million

  • "2011 was a highly successful year that saw the FDA approval and U.S. launch of DIFICID as well as European approval. The early launch is highly impactful and we believe interest in DIFICID from physicians, payors and hospitals, coupled with the benefit it can provide patients, will translate into robust growth in product adoption and sales as the launch matures," said Pedro Lichtinger, Optimer's President and CEO. "In 2012 we are starting a series of additional initiatives to support further growth, including a focus on the Long Term Care market, improving access, initiating clinical trials intended to expand our label, and entering new markets including Europe through our collaboration with Astellas and Canada through a direct commercialization effort."

    Fourth Quarter and Fiscal Year 2011 Financials:For the fiscal year 2011 total revenues were $145 million, compared to $1.5 million for the fiscal year 2010. Total revenues for the fourth quarter 2011 were $64.6 million, compared with $156,000 for the fourth quarter 2010. The increases in revenues were primarily due to an upfront payment received from Astellas Pharma Europe in the first quarter and an EMA approval milestone earned in the fourth quarter in connection with the DIFICID license agreement in Europe, as well as the July 18, 2011 commerci
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
    2. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
    3. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
    4. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    5. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    6. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
    7. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
    8. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
    9. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
    10. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
    11. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
    (Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
    (Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
    Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
    (Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
    (Date:4/17/2014)... relief targets that could be used to provide ... College London made the discovery when researching how ... the body. , Dr Marzia Malcangio said: "We ... generation and our findings could help chemotherapy patients ... potential side effect of some chemotherapy drugs (such ...
    (Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
    (Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
    (Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
    Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2
    ... Association (NMA), the nation,s premier membership organization for ... amount of $120,000 from the W.K. Kellogg Foundation. ... grant commitment, designed "to promote health care coverage ... partner organizations."Partner organizations for this effort include Families ...
    ... in urban areas , , TUESDAY, April 21 (HealthDay News) -- ... areas are not less likely to get a kidney transplant ... , Researchers analyzed U.S. data on 699,751 adults with kidney ... 1995 and 2007. After about two years on the list, ...
    ... reduced risk of relapse or death, study finds , , ... lymphoma who drank wine before their diagnosis appeared to ... to a study that,s the first to identify this ... women with non-Hodgkin lymphoma and found that, overall, those ...
    ... your memory will get worse as you get older may ... University have found that senior citizens who think older people ... worse than seniors who do not buy in to negative ... published earlier this month, psychology professor Dr. Tom Hess and ...
    ... April 21 DaVita Inc. (NYSE: ... services for those diagnosed with chronic kidney disease ... as the company,s Senior Vice President of Federal ... public policy efforts in Washington, D.C. and report ...
    ... quality care needs in skilled nursing facilitiesCOLUMBUS, Ohio, ... Nursing Care Coalition, the umbrella group representing Ohio,s ... of the state budget bill unveiled by House ... services to Ohio,s frail elderly and disabled citizens ...
    Cached Medicine News:Health News:National Medical Association Receives Funding From Kellogg for Training Community Advocates 2Health News:Distance No Bar to Kidney Transplants in Remote Areas 2Health News:Wine May Guard Against Lymphoma Recurrence 2Health News:Think memory worsens with age? Then yours probably will 2Health News:John Schaeffler Appointed Senior Vice President for Federal Legislative Affairs 2Health News:Skilled Nursing Care Coalition Praises House Leadership for Budget Changes 2
    For the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma....
    For the quantitative in vitro determination of Carbamazepine in human serum...
    For the quantitative in vitro determination of Phenobarbital in human serum....
    Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
    Medicine Products: